Barely Significant
← all excerpts

Comparison Between Alpelisib Plus Endocrine Therapy and Everolimus Plus Endocrine Therapy After CDK4/6 Inhibitors Progression in Patients with <i>PIK3CA</i>-Mutant Metastatic Breast Cancer: A Single-Center Retrospective Study.

Cancers (Basel) · 2026 · PMC12896634 · PMID 41681940

Europe PMCDOI
1
hedged sentence
0.5300
closest p · 10.6× alpha
0.5300
boldest claim

The sentences

did not reach statistical significancep = 0.53not close (p > 0.1)
The median PFS for alpelisib group was 4.9 months compared to 4.5 months in the everolimus group, and the difference did not reach statistical significance (HR, 1.22; 95% CI, 0.65–2.28; p = 0.53).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.